SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer-MedSci.cn

SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer

Oliveira, M; Andujar, JMC; Vila, MM; Ortega, PT; Saez, OM; Bofill, FJS; Jurado, JC; Barrera, AML; De Dios, MAA; Losada, MJV; Guerra, JA; Simon, SP; Javierre, GV; Gonzalez-Farre, B; Torres, ES; Santhanagopal, A; Falato, C; Cafiero, JMF; Pascual, T; Prat, A

ANNALS OF ONCOLOGY, 2022; 33 (7): S628

科室
- - 订阅+
  - 更多科室
工具
服务